Breast cancer targeted therapy drugs block the action of abnormal kinases, such as human epidermal growth factor receptor 2 (HER2) and cyclin-dependent kinase (CDK) 4 and 6, which stimulate the growth of breast cancer cells in specific ways (Gu et al., 2016). The gene discussed is ERBB2; the disease is breast carcinoma.